HC Wainwright & Co. Reiterates Buy on Ligand Pharmaceuticals, Maintains $144 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Ligand Pharmaceuticals (NASDAQ:LGND) and maintained a price target of $144.
August 08, 2024 | 10:48 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Ligand Pharmaceuticals and maintained a price target of $144.
The reiteration of a Buy rating and a maintained price target of $144 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100